雄激素及其受体在肝细胞癌中的研究进展  

Research progress on androgens and androgen receptor in hepatocellular carcinoma

作　　者：赵伟[1] 张秀娜[1] 周有丽 杨勇[2] 陈真[3] 

机构地区：[1]中国药科大学药学院,江苏南京211198 [2]中国药科大学药物研究院,江苏南京211198 [3]中国药科大学药学医学基础实验教学中心,江苏南京211198

出　　处：《药学研究》2015年第3期168-171,共4页Journal of Pharmaceutical Research

基　　金：国家自然科学基金(No.21372260);江苏省2014年度普通高校研究生科研创新计划项目(No.SJLX_0287)

摘　　要：肝细胞癌是最常见的原发性肝癌,也是激素敏感性肿瘤之一。在人类及啮齿类动物中肝癌发生均表现出一定的性别差异。这种差异可能与性激素有关,雄激素受体对肝癌发生、进展、转移具有一定的作用。本文阐述了雄激素受体与肝癌发生、进展、转移的关系及其可能的分子机制。雄激素受体可作为肝癌个性化治疗的一个潜在靶标,辅助现有治疗药物或为临床诊断、预后评估、肿瘤分级提供理论参考。Hepatocellular carcinoma is one of the most common primary liver cancer,which has been considered a hormone- dependent tumor. Similar gender disparity is seen in men and mice. The gender differences may be related to sex hormones,and androgen receptor may play a role in initiation and development besides metastasis in HCC. In this review,we described the relationship between androgen receptor and the initiation and development besides metastasis of HCC,along with the possible molecular mechanisms. Androgen receptor may be an potential target in the personalized treatment,auxiliary existing medicines and providing the reference for the clinical diagnosis and prognosis prediction as well as grading of tumor.

关 键 词：肝细胞癌 性激素 雄激素受体 分子机制 

分 类 号：R735.7[医药卫生—肿瘤]